2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Calcium Phosphate Ceramics Can Prevent Bisphosphonate-Related Osteonecrosis of the Jaw

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Bisphosphonate-associated osteonecrosis of the jaw (BRONJ), a post-surgical non-healing wound condition, is one of the most common side effects in patients treated with nitrogen-containing bisphosphonates. Its physiopathology has been related with suppression of bone turnover, of soft tissue healing and infection. Biphasic calcium phosphates (BCP) are used as a drug delivery vehicle and as a bone substitute in surgical wounds. Due to their capacity to adsorb zoledronate, it was hypothesized these compounds might have a protective effect on the soft tissues in BRONJ wounds. To address this hypothesis, a reproducible in vivo model of BRONJ in Wistar rats was used. This model directly relates chronic bisphosphonate administration with the development of osteonecrosis of the jaw after tooth extraction. BCP granules were placed in the alveolus immediately after tooth extraction in the test group. The animals were evaluated through nuclear medicine, radiology, macroscopic observation, and histologic analysis. Encouragingly, calcium phosphate ceramics were able to limit zoledronate toxicity in vivo and to favor healing, which was evidenced by medical imaging (nuclear medicine and radiology), macroscopically, and through histology. The studied therapeutic option presented itself as a potential solution to prevent the development of maxillary osteonecrosis.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Fibroblasts and myofibroblasts in wound healing

          (Myo)fibroblasts are key players for maintaining skin homeostasis and for orchestrating physiological tissue repair. (Myo)fibroblasts are embedded in a sophisticated extracellular matrix (ECM) that they secrete, and a complex and interactive dialogue exists between (myo)fibroblasts and their microenvironment. In addition to the secretion of the ECM, (myo)fibroblasts, by secreting matrix metalloproteinases and tissue inhibitors of metalloproteinases, are able to remodel this ECM. (Myo)fibroblasts and their microenvironment form an evolving network during tissue repair, with reciprocal actions leading to cell differentiation, proliferation, quiescence, or apoptosis, and actions on growth factor bioavailability by binding, sequestration, and activation. In addition, the (myo)fibroblast phenotype is regulated by mechanical stresses to which they are subjected and thus by mechanical signaling. In pathological situations (excessive scarring or fibrosis), or during aging, this dialogue between the (myo)fibroblasts and their microenvironment may be altered or disrupted, leading to repair defects or to injuries with damaged and/or cosmetic skin alterations such as wrinkle development. The intimate dialogue between the (myo)fibroblasts and their microenvironment therefore represents a fascinating domain that must be better understood in order not only to characterize new therapeutic targets and drugs able to prevent or treat pathological developments but also to interfere with skin alterations observed during normal aging or premature aging induced by a deleterious environment.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Epidemiology and pathogenesis of osteonecrosis of the jaw.

              Osteonecrosis of the jaw (ONJ) is defined as exposed bone in the oral cavity that persists despite appropriate therapy. Over the past decade, ONJ has been reported in about 5% of patients with cancer receiving high-dose intravenous bisphosphonates, and more recently in similar patients treated with denosumab, another potent inhibitor of osteoclastic bone resorption. The condition has also been described in patients treated with bisphosphonates for benign diseases, such as osteoporosis, but whether bisphosphonates or denosumab increase the incidence above that seen in untreated patients of comparable age and frailty is yet to be established. The pathogenesis of ONJ is uncertain: the toxic effects of bisphosphonates in a wide variety of cells could increase susceptibility to infections in the oral cavity or impair mucosal healing, and denosumab might interfere with monocyte and macrophage function. Local osteolysis is an important defense against infection on bone surfaces that is blocked by both bisphosphonates and denosumab. Preventive dentistry prior to high-dose antiresorptive therapy is a critical measure in cancer patients, but is not usually justified in patients with osteoporosis. The management of established ONJ lesions is problematic: the greatest success seems to come from vigorous antimicrobial therapy with judicious use of surgical debridement.
                Bookmark

                Author and article information

                Journal
                Materials (Basel)
                Materials (Basel)
                materials
                Materials
                MDPI
                1996-1944
                22 April 2020
                April 2020
                : 13
                : 8
                : 1955
                Affiliations
                [1 ]Institute of Endodontics, Faculty of Medicine, University of Coimbra, 3000-075 Coimbra, Portugal
                [2 ]Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment, Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal; mafaldalaranjo@ 123456gmail.com (M.L.); anabelabppaula@ 123456sapo.pt (A.P.); amabrantes@ 123456fmed.uc.pt (A.M.A.); cmiguel.marto@ 123456uc.pt (C.M.M.); anasofiacoelho@ 123456gmail.com (A.C.); lcarvalho@ 123456huc.min-saude.pt (L.C.); eunicecarrilho@ 123456gmail.com (E.C.); mfbotelho@ 123456fmed.uc.pt (M.F.B.)
                [3 ]Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal
                [4 ]Clinical and Academic Centre of Coimbra (CACC), 3004-561 Coimbra, Portugal
                [5 ]Institute of Biophysics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
                [6 ]Institute of Integrated Clinical Practice, Faculty of Medicine, University of Coimbra, 3000-075 Coimbra, Portugal
                [7 ]Department of Endodontology, Academic Center of Dentistry Amsterdam, University of VU Amsterdam, De Boelelaan 1105, 1081 HV Amsterdam, The Netherlands; jfbrochado@ 123456gmail.com
                [8 ]Institute of Experimental Pathology, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
                [9 ]Radiation Oncology Service, Coimbra Hospital and University Centre, 3004-561 Coimbra, Portugal; joao.casalta@ 123456gmail.com
                [10 ]Institute of Anatomical and Molecular Pathology, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal
                [11 ]Department of Chemical Engineering, Faculty of Sciences and Technology, University of Coimbra (FCTUC), 3030-790 Coimbra, Portugal; armenio.serra@ 123456gmail.com
                Author notes
                [* ]Correspondence: sirivpaulo@ 123456gmail.com (S.P.); mmferreira@ 123456fmed.uc.pt (M.M.F.); Tel.: +351-914-756-654 (S.P.); +351-966-041-836 (M.M.F.)
                Author information
                https://orcid.org/0000-0002-3914-2423
                https://orcid.org/0000-0003-0689-6007
                https://orcid.org/0000-0001-6154-4173
                https://orcid.org/0000-0002-3473-5801
                https://orcid.org/0000-0001-9269-5417
                https://orcid.org/0000-0002-2924-7926
                https://orcid.org/0000-0002-5759-5557
                https://orcid.org/0000-0001-8664-2757
                https://orcid.org/0000-0001-7202-1650
                https://orcid.org/0000-0002-5968-6161
                Article
                materials-13-01955
                10.3390/ma13081955
                7215435
                32331240
                b588f781-0e3e-4bb8-bced-668f081aa5a5
                © 2020 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 31 March 2020
                : 20 April 2020
                Categories
                Article

                animal models,bisphosphonate-related osteonecrosis of the jaw (bronj),biphasic calcium phosphates (bcp),zoledronate

                Comments

                Comment on this article